Shirt a Phobia

Sample Page

EcPLA, also known as N-ethyl-N-cyclopropyllysergamide or as lysergic acid ethylcyclopropylamide (LAEcP), is a psychedelic drug of the lysergamide family related to lysergic acid diethylamide (LSD).[2][3][4] It is an isomer of LSZ and is closely related to other amide-substituted lysergamides like MiPLA.[3][2][5][4] The drug has been encountered as a novel designer drug.[4]

Use and effects

EcPLA produces psychedelic effects in humans.[4]

Interactions

See also: Psychedelic drug § Interactions, and Trip killer § Serotonergic psychedelic antidotes

Pharmacology

Pharmacodynamics

EcPLA has been found to interact with serotonin receptors and dopamine receptors, among other targets. It is a high potency agonist of the serotonin receptors, with its highest binding affinities at the 5-HT1A (Ki = 3.2 nM), 5-HT2B (Ki = 5.3 nM), and 5-HT5A (Ki = 8.6 nM) subtypes. Its 5-HT2A affinity is equivalent to that of LSD, while the affinity to 5-HT2C receptors is 3 times lower than LSD. It shares much of its binding profile with LSD, but does not bind to β1 or β2 adrenergic receptors as LSD does.[3]

The drug produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents. It has about 40% of the potency of LSD in this regard.[3]

Pharmacokinetics

The in-vitro metabolism of EcPLA has been studied.[6]

Chemistry

Analogues

Analogues of EcPLA include MiPLA, LAMPA (MPLA), EPLA, EiPLA, ETFELA, and LSZ, among others.[5][3][2]

History

EcPLA was first described in the scientific literature by a team that included Adam Halberstadt, Alexander Stratford, Jason Wallach, and David E. Nichols in 2019.[3] It was developed by Lizard Labs.[citation needed] The drug was encountered online as a novel designer drug in around 2020 and became more widely available in early 2022.[4]

See also

References

  1. ^ “Arrêté du 20 mai 2021 modifiant l’arrêté du 22 février 1990 fixant la liste des substances classées comme stupéfiants”. www.legifrance.gouv.fr (in French). 20 May 2021.
  2. ^ a b c Kavanagh PV, Westphal F, Stratford A, Elliott SP, Dowling G, Halberstadt AL, et al. (2020). “Analytical profile of N-ethyl-N-cyclopropyl lysergamide (ECPLA), an isomer of lysergic acid 2,4-dimethylazetidide (LSZ)”. Drug Testing and Analysis. 12 (10): 1514–1521. doi:10.1002/dta.2911. ISSN 1942-7611. PMC 9191644. PMID 32803833.
  3. ^ a b c d e f Halberstadt AL, Klein LM, Chatha M, Valenzuela LB, Stratford A, Wallach J, et al. (February 2019). “Pharmacological characterization of the LSD analog N-ethyl-N-cyclopropyl lysergamide (ECPLA)”. Psychopharmacology. 236 (2): 799–808. doi:10.1007/s00213-018-5117-z. PMC 6848745. PMID 30298278.
  4. ^ a b c d e “ECPLA”. АИПСИН (in Russian). Retrieved 1 January 2026.
  5. ^ a b Wachełko O, Nowak K, Tusiewicz K, Zawadzki M, Szpot P (January 2025). “A highly sensitive UHPLC-MS/MS method for determining 15 designer LSD analogs in biological samples with application to stability studies”. Analyst. 150 (2): 290–308. doi:10.1039/d4an01361a. PMID 39636448.
  6. ^ Wagmann L, Richter LH, Kehl T, Wack F, Bergstrand MP, Brandt SD, et al. (July 2019). “In vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures” (PDF). Analytical and Bioanalytical Chemistry. 411 (19): 4751–4763. doi:10.1007/s00216-018-1558-9. PMID 30617391. S2CID 58615418.